Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 July 2019
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant [TS ID 11868]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC